Cargando…

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm

BACKGROUND: The BRAF(V600E) mutation is the most common genetic alteration identified in papillary thyroid carcinoma (PTC). Because of its costs effectiveness and sensitivity, direct Sanger sequencing has several limitations. The aim of this study was to evaluate the efficiency of immunohistochemist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Hye-Seon, Kwon, Hyemi, Park, Suyeon, Kim, Mijin, Jeon, Min Ji, Kim, Tae Yong, Shong, Young Kee, Kim, Won Bae, Choi, Jene, Kim, Won Gu, Song, Dong Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874197/ https://www.ncbi.nlm.nih.gov/pubmed/29388401 http://dx.doi.org/10.3803/EnM.2018.33.1.62

Ejemplares similares

Expression of NF2 Modulates the Progression of BRAF(V600E) Mutated Thyroid Cancer Cells
por: You, Mi-Hyeon, et al.
Publicado: (2019)

Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
por: Kwon, Hyemi, et al.
Publicado: (2016)

Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules
por: Kwon, Hyemi, et al.
Publicado: (2016)

Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAF(V600E)-Mutant Advanced Papillary Thyroid Carcinoma
por: Song, Eyun, et al.
Publicado: (2021)

Thyrotoxic Periodic Paralysis and Polymorphisms of the ADRB2, AR, and GABRA3 Genes in Men with Graves Disease
por: Park, Suyeon, et al.
Publicado: (2016)

Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
por: Jeon, Min Ji, et al.
Publicado: (2016)

Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010
por: Choi, Yun Mi, et al.
Publicado: (2014)

Solitary Skin Metastasis of Papillary Thyroid Carcinoma
por: Kwon, Hyemi, et al.
Publicado: (2014)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

Lack of Associations between Body Mass Index and Clinical Outcomes in Patients with Papillary Thyroid Carcinoma
por: Kwon, Hyemi, et al.
Publicado: (2015)

Erratum: Figure Correction: Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010
por: Choi, Yun Mi, et al.
Publicado: (2015)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF (V600E) mutation in papillary thyroid carcinoma
por: Wang, Zhuo, et al.
Publicado: (2019)

Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues
por: Zhang, Yini, et al.
Publicado: (2021)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
por: Ihle, Michaela Angelika, et al.
Publicado: (2014)

Impact of Reclassification on Thyroid Nodules with Architectural Atypia: From Non-Invasive Encapsulated Follicular Variant Papillary Thyroid Carcinomas to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features
por: Jeon, Min Ji, et al.
Publicado: (2016)

VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAF(V600E) Mutation in Papillary Thyroid Cancer
por: Choden, Sonam, et al.
Publicado: (2020)

Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

Postoperative Findings and Risk for Malignancy in Thyroid Nodules with Cytological Diagnosis of the so-called “Follicular Neoplasm”
por: Kim, Eun Sook, et al.
Publicado: (2003)

Association between urinary sodium levels and iodine status in Korea
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
por: Kim, Woon Won, et al.
Publicado: (2018)

Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer
por: Kim, Won Bae, et al.
Publicado: (2020)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

Changes in the Pulmonary Function Test after Radioactive Iodine Treatment in Patients with Pulmonary Metastases of Differentiated Thyroid Cancer
por: Jang, Eun Kyung, et al.
Publicado: (2015)

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
por: Gow, Chien-Hung, et al.
Publicado: (2019)

Correlation of the Expression of BRAF V600E Mutation With Various Phenotypic Expressions of Thyroid Neoplasms
por: Harikrishnan, Volga, et al.
Publicado: (2021)

Modification of the Tumor-Node-Metastasis Staging System for Differentiated Thyroid Carcinoma by Considering Extra-Thyroidal Extension and Lateral Cervical Lymph Node Metastasis
por: Kim, Mijin, et al.
Publicado: (2020)

Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
por: Han, Ji Min, et al.
Publicado: (2018)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

Graves’ disease diagnosed in remnant thyroid after lobectomy for thyroid cancer
por: Jin, Meihua, et al.
Publicado: (2022)

VE1 immunohistochemistry is an adjunct tool for detection of BRAF (V600E) mutation: Validation in thyroid cancer patients
por: Rashid, Faiza A., et al.
Publicado: (2020)

Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
por: Jeon, Min Ji, et al.
Publicado: (2021)

Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
por: Jeon, Min Ji, et al.
Publicado: (2022)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

Cross-Regulation between Oncogenic BRAF(V600E) Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
por: Lee, Seong Jin, et al.
Publicado: (2011)

Current Status and Future Perspectives in Differentiated Thyroid Cancer
por: Kim, Tae Yong, et al.
Publicado: (2014)

The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma
por: Ramkumar, Subramaniam, et al.
Publicado: (2021)

Reference interval for thyrotropin in a ultrasonography screened Korean population
por: Kim, Mijin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fr54m4le703vqmds6alipagha1